|Mr. Jean-Francois Mouney||Co-Founder & Chairman||252.14k||N/A||1955|
|Mr. M. Pascal Prigent||Chief Exec. Officer||430.29k||N/A||1968|
|Prof. Bart Staels||Co-Founder & Chairman of the Scientific Advisory Board||N/A||N/A||1963|
|Mr. Thomas Baetz||Chief Financial Officer||N/A||N/A||1974|
|Mr. Pascal Caisey||Chief Operating Officer||N/A||N/A||1969|
|Dr. Dean W. Hum Ph.D.||Chief Scientific Officer||N/A||N/A||1962|
|Mr. Laurent Lannoo||Corp. Sec. & Director of Legal Affairs||N/A||N/A||1970|
|Ms. Stefanie Magner||Chief Compliance Officer & VP of International Legal Affairs||N/A||N/A||1981|
|Ms. Emilie Desodt||Vice-Pres of HR||N/A||N/A||N/A|
|Mr. Jean-Christophe Marcoux||Chief Strategy Officer||N/A||N/A||1977|
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Genfit S.A.’s ISS governance QualityScore as of 1 May 2022 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 4; Compensation: 9.